Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
Toxiciteit van CAR T-celtherapie goed hanteerbaar bij patiënten met recidiverend of refractair multipel myeloom
aug 2023 | MM